key: cord-0947486-1xcfwr00 authors: Li, Yijia; Li, Jonathan Z. title: SARS-CoV-2 Virology date: 2022-01-31 journal: Infect Dis Clin North Am DOI: 10.1016/j.idc.2022.01.004 sha: fae985978815a0675516564f641524e73032d812 doc_id: 947486 cord_uid: 1xcfwr00 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was first identified in 2020 and has led to an unprecedented global pandemic. Understanding the virology behind SARS-CoV-2 infection has provided key insights into our efforts to develop antiviral agents and to control the COVID-19 pandemic. In this review, we focus on the genomic features of SARS-CoV-2, its intra-host and inter-host evolution, viral dynamics in respiratory tract, and systemic dissemination. immunocompromised patients infected with SARS-CoV-2 further support the negative correlation 143 between host immunity and accelerated intra-host evolution 38-40 . 144 From the population level, inter-host mutations and evolution have certainly complicated this 145 pandemic by multiple folds. D614G mutation on Spike protein was the first major mutation discovered 146 since the beginning of this pandemic. D614G was rare before March 2020 but rapidly became the 147 globally dominant mutation since May 2020 41 . This mutation is associated with enhanced infectivity and 148 replication compared to the original strain with D614 41,42 . This enhanced infectivity is mediated by an 149 increase in Furin cleavage efficiency and more frequent RBD "up" state 43 that characterizes a 150 conformation facilitating ACE2 accessibility 44 . However, G614 and D614 strains have similar level of 151 susceptibility to neutralization from convalescent plasma/serum 45 . With further global spread and 152 replication, SARS-CoV-2 continues to diversify and has developed into multiple circulating variants. By 153 the beginning of 2022, there have been 5 major variants of concern (VOC) and 6 variants of interest 154 (VOI) documented on the GISAID database 46, 47 . We have summarized the VOCs and certain VOIs in 155 in the Delta variant, is associated with decrease in HLA-A24 or HLA-A02 restricted CD8+ T cell 171 response to the T cell epitope containing this mutation 62,63 . Third, the Delta variant is associated with 172 more efficient membrane fusion independent of better ACE2 binding. Zhang and colleagues 173 demonstrated that Delta strain had higher fusion activity towards target cells in an in vitro system 174 without having higher affinity to ACE2 compared to other variants 56 . Last but not the least, Syed 175 Abdullah and colleagues used a SARS-CoV-2 virus-like particle model and demonstrated that key 176 Nucleocapsid mutations found in Delta variant, including R203M, are associated with enhanced viral 177 RNA packaging and replication 64 . While the Beta and Gamma variants mediate a greater degree of 178 escape against vaccine or natural immunity-mediated immune responses, the greater transmissibility of 179 Delta allowed it to supplant these variants. Together, the features above enable Delta variant to 180 transmit efficiently and evade pre-existing adaptive immunity, leading to higher viral shedding in the 181 upper respiratory tract 65,66 , more rapid transmission 67 , and vaccine "breakthrough" infection 68 compared 182 to ancestral strains. Fortunately, vaccination is still associated more rapid viral clearance in those Delta 183 breakthrough cases compared to unvaccinated cases 69 . 184 The Omicron variant, first reported in South Africa in November 2021, has further led this 185 pandemic into an uncharted water. The rate that the Omicron variant has spread world-wide has been 186 unprecedented and it has become the dominant strain world-wide 58 Understanding the virology behind SARS-CoV-2 infection has provided key insights into our efforts to 293 develop antiviral agents and to control the pandemic. However, there remains substantial gaps in our 294 J o u r n a l P r e -p r o o f knowledge of SARS-CoV-2 biology and pathogenesis. Studies are needed to further dissect the 295 functions of each non-structural and accessory proteins and how they contribute to the pathogenesis of 296 SARS-CoV-2. In addition, we need to understand the roles of the multiple mutations in the newly 297 emergent variants (e.g., Omicron variant) and how they contribute to increased transmission and 298 immune evasion. There are also increasing questions on the role of systemic viral dissemination in the 299 pathogenesis of severe disease and the detection of viremia as a prognostic marker. Furthermore, we 300 know relatively little about the animal reservoirs of SARS-CoV-2 and their potential to fuel the 301 emergence of new variants. The answers to these questions will be crucial as we devise improved 302 vaccine strategies and antiviral therapies. 303 304 Clinics Care Points 305  Immunocompromised patients are at higher risk of developing immune escape mutations and 306 prolonged SARS-CoV-2 infection. 307  SARS-CoV-2 has different replication dynamics in the upper and lower respiratory tracts 308  SARS-CoV-2 viremia and dissemination are associated with worse outcomes. 309 Genomic characterisation and epidemiology of 2019 novel coronavirus: 311 implications for virus origins and receptor binding Clinical features of patients infected with 2019 novel coronavirus 313 in Wuhan SARS-CoV-2 setting-specific transmission rates: a 318 systematic review and meta-analysis. Clin Infect Dis. 2021. 319 5. The pandemic's true death toll A pneumonia outbreak associated with a new coronavirus of 322 probable bat origin Identifying SARS-CoV-2-related coronaviruses in Malayan 324 pangolins Identification of novel bat coronaviruses sheds light on the 326 evolutionary origins of SARS-CoV-2 and related viruses A novel SARS-CoV-2 related coronavirus in bats from 328 Dysregulation of Cell Signaling by 330 SARS-CoV-2 Structural basis for translational shutdown and 332 immune evasion by the Nsp1 protein of SARS-CoV-2 Coronavirus RNA Proofreading: Molecular Basis and 334 Therapeutic Targeting SARS-CoV-2 Accessory Proteins in Viral 336 Pathogenesis: Knowns and Unknowns Activation and evasion of type I interferon responses by SARS-CoV-338 2 Evasion of Type I Interferon by SARS-CoV-2 The ORF8 protein of SARS-CoV-2 mediates immune evasion 342 through down-regulating MHC-Ι A SARS-CoV-2 protein interaction map reveals 344 targets for drug repurposing Structure of replicating 346 SARS-CoV-2 polymerase Remdesivir for the Treatment of Covid-19 -Final 348 Report Early Remdesivir to Prevent Progression to Severe 350 Covid-19 in Outpatients Crystallographic structure of wild-type SARS-CoV-2 main 352 protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site An oral SARS-CoV-2 Mpro 355 inhibitor clinical candidate for the treatment of COVID-19 Fact sheet for healthcare providers: Emergency Use Authorization for Paxlovid The furin cleavage site in the SARS-CoV-2 spike protein 359 is required for transmission in ferrets Structure, Function, and 361 Antigenicity of the SARS-CoV-2 Spike Glycoprotein Loss of furin cleavage site attenuates SARS-CoV-2 363 pathogenesis Cell entry mechanisms of SARS-CoV-2. Proceedings of the 365 National Academy of Sciences Bamlanivimab plus Etesevimab in Mild or Moderate Covid-369 19 The NSP14/NSP10 RNA repair complex as a Pan-371 coronavirus therapeutic target. Cell Death & Differentiation. 2021. 372 31 SARS-CoV-2 within-host diversity and transmission. 376 Science SARS-CoV-2 genomic analyses in cancer patients 378 reveal elevated intrahost genetic diversity SARS-CoV-2 Sequence Characteristics of 380 COVID-19 Persistence and Reinfection Persistence and Evolution of SARS-CoV-2 in an 382 Immunocompromised Host SARS-CoV-2 evolution in an immunocompromised host 384 reveals shared neutralization escape mechanisms Prospective mapping of viral mutations that escape 386 antibodies used to treat COVID-19 Replication in a CAR-T-cell Therapy Recipient: A Case Study Successful Clearance of 300 Day SARS-CoV-2 390 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-391 COV Anti-Spike Monoclonal Antibody Cocktail De novo emergence of a remdesivir resistance mutation 393 during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case 394 report. medRxiv Tracking Changes in SARS-CoV-2 Spike: 396 Evidence that D614G Increases Infectivity of the COVID-19 Virus Spike mutation D614G alters SARS-CoV-2 fitness D614G Mutation Alters SARS-CoV-2 Spike 401 Conformation and Enhances Protease Cleavage at the S1/S2 Junction Distinct conformational states of SARS-CoV-2 spike protein. 404 Science The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and 406 Antigenicity disease and diplomacy: GISAID's innovative contribution to 408 global health. Global challenges GISAID Antibody cocktail to SARS-CoV-2 spike protein prevents 411 rapid mutational escape seen with individual antibodies Recurrent deletions in the SARS-CoV-2 spike 413 glycoprotein drive antibody escape Durability of mRNA-1273 vaccine-induced antibodies 415 against SARS-CoV-2 variants SARS-CoV-2 Variants and Vaccines SARS-CoV-2 Lambda 419 Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and 420 Convalescent Serum Reduced sensitivity of SARS-CoV-2 variant Delta to 422 antibody neutralization Infection and Vaccine-Induced Neutralizing-Antibody 424 Responses to the SARS-CoV-2 B.1.617 Variants Neutralization of the SARS-CoV-2 Mu Variant by 427 Convalescent and Vaccine Serum Membrane fusion and immune evasion by the spike protein of 429 SARS-CoV-2 Delta variant Lineage 431 Comparison Outbreakinfo Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus 437 Compounds Effectiveness of Covid-19 Vaccines against the 439 B.1.617.2 (Delta) Variant Identification of SARS-CoV-2 spike mutations that 441 attenuate monoclonal and serum antibody neutralization Profiling CD8+ T Cell Epitopes of COVID-19 Convalescents 444 Reveals Reduced Cellular Immune Responses to SARS-CoV-2 Variants SARS-CoV-2 spike L452R variant evades cellular 446 immunity and increases infectivity Rapid assessment of SARS-CoV-2 evolved 448 variants using virus-like particles Clinical and virological features of SARS-CoV-2 variants of 450 concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 451 (Delta) The Delta SARS-CoV-2 variant has a higher viral 453 load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed 454 COVID-19 The reproductive number of the Delta variant of SARS-CoV-2 is far higher 456 compared to the ancestral SARS-CoV-2 virus Virological characteristics of SARS-CoV-2 vaccine 461 breakthrough infections in health care workers. medRxiv Omicron escapes the majority of existing SARS-CoV-2 463 neutralizing antibodies The dual function monoclonal antibodies 465 VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. 466 bioRxiv mRNA-based COVID-19 vaccine boosters 468 induce neutralizing immunity against SARS-CoV-2 Omicron variant Striking Antibody Evasion Manifested by the Omicron Variant of 470 SARS-CoV-2 Reduced Neutralization of SARS-CoV-2 Omicron 472 Variant by Vaccine Sera and monoclonal antibodies. medRxiv Reduced neutralisation of SARS-CoV-2 omicron 475 B.1.1.529 variant by post-immunisation serum Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection Vaccines Elicit Highly Cross-Reactive Cellular 479 Immunity to the SARS-CoV-2 Omicron Variant. medRxiv T cell reactivity to the SARS-CoV-2 Omicron variant is 481 preserved in most but not all prior infected and vaccinated individuals. medRxiv Reduced interferon 484 antagonism but similar drug sensitivity in Omicron variant compared to Delta CoV-2 isolates Reduced Pathogenicity of the SARS-CoV-2 Omicron 487 Variant in Hamsters SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less 489 severe disease than Pango B and Delta variants strains in a mouse model of severe SARS-CoV-2 Omicron spike mediated immune 492 escape, infectivity and cell-cell fusion Characteristics and 494 Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave 495 Compared With Previous Waves The SARS-CoV-2 Spike protein has a broad tropism 497 for mammalian ACE2 proteins Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine 499 efficacy Transmission of SARS-CoV-2 in domestic cats 501 imposes a narrow bottleneck Transmission of SARS-CoV-2 on 503 mink farms between humans and mink and back to humans The SARS-CoV-2 Y453F mink variant displays 505 a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization SARS-CoV-2 infection in free-ranging white-tailed deer. 508 Nature SARS-CoV-2 entry factors are highly expressed in 510 nasal epithelial cells together with innate immune genes SARS-CoV-2 Reverse Genetics Reveals a Variable 512 Infection Gradient in the Respiratory Tract Virulence and pathogenesis of SARS-CoV-2 infection in rhesus 514 macaques: A nonhuman primate model of COVID-19 progression Virological assessment of hospitalized patients with 517 COVID-2019 Viral Load Kinetics of SARS-CoV-2 In Hospitalized 519 Individuals with COVID-19. Open Forum Infectious Diseases Detection of SARS coronavirus 521 in plasma by real-time RT-PCR Influenza viral RNA detection in blood as a marker to 523 predict disease severity in hematopoietic cell transplant recipients Respiratory syncytial virus lower respiratory disease in 526 hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and 527 clinical outcomes Incidence and treatment strategy for disseminated 529 adenovirus disease after haploidentical stem cell transplantation SARS-CoV-2 viremia is associated with distinct proteomic 532 pathways and predicts COVID-19 outcomes SARS-CoV-2 RNA in plasma is associated with ICU 534 admission and mortality in patients hospitalized with COVID-19 SARS-CoV-2 RNAemia and proteomic trajectories 536 inform prognostication in COVID-19 patients admitted to intensive care Detectable Serum Severe Acute Respiratory Syndrome 539 Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 540 Level in Critically Ill Patients With Coronavirus Disease RNAemia Corresponds to Disease 543 Severity and Antibody Response in Hospitalized COVID-19 Patients Viral RNA load in plasma is 547 associated with critical illness and a dysregulated host response in COVID-19 SARS-CoV-2 detection in the lower respiratory tract of 550 invasively ventilated ARDS patients Clinical Course and Molecular Viral Shedding Among Asymptomatic 552 and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the 553 Republic of Korea Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA 557 levels but not symptom duration in non-hospitalized adults with COVID-19. medRxiv A cohort autopsy study defines COVID-19 systemic pathogenesis. 560 Cell research Multi-organ proteomic landscape of COVID-19 autopsies SARS-CoV-2 productively infects human gut 564 enterocytes Direct Evidence of Active SARS-CoV-2 Replication in the Intestine. 566 Clinical Infectious Diseases Fecal SARS-CoV-2 RNA is associated with 568 decreased COVID-19 survival SARS-CoV2 vertical transmission with adverse effects on 572 the newborn revealed through integrated immunohistochemical, electron microscopy and 573 molecular analyses of Placenta Renal histopathological analysis of 26 postmortem findings of 575 patients with COVID-19 in China Pulmonary Vascular Endothelialitis, Thrombosis, 577 and Angiogenesis in Covid-19 Characterizing Viral Infection by Electron Microscopy: 579 Lessons from the Coronavirus Disease 2019 Pandemic Best practices for correctly identifying coronavirus by 581 transmission electron microscopy COVID-19 OUTCOME: INSIGHTS FROM 583 QUANTIFICATION OF VIREMIA AND NEUTRALIZING ANTIBODY. Abstract 116. Virtual 584 Conference on Retroviruses and Opportunistic Infections (vCROI) Lipid droplets fuel SARS-CoV-2 replication and 586 production of inflammatory mediators SARS-CoV-2 infects blood monocytes to activate 588 NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release SARS-CoV-2 genome structure. In SARS-CoV-2 genome, ORF1a/1b encodes polypeptides 593 that undergo viral protease-mediated cleavage to non-structural proteins 1-16